Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A nationwide Danish study links prolonged residential road traffic noise exposure with increased Parkinson disease risk, highlighting the protective effect of having a quiet building facade.
A large Sweden-France analysis suggests rising MS prevalence is mainly survival-driven, increasing MND prevalence reflects growing incidence, and PD prevalence rises modestly through mixed demographic and survival effects.
In a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.
Resting-state MRI and PET data suggest that corticostriatal networks remodel across nigrostriatal degeneration in Parkinson disease, with posterior caudate hyperconnectivity preceding major motor decline and posterior putaminal disconnectio
The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a novel selective D1/D5 agonist, significantly improves daily ‘good-on-time’ and reduces ‘off-time’ in Parkinson’s disease patients with motor fluctuations, pres
A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.
Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to adv
A 12-week randomized trial demonstrates that behavioral therapy is noninferior to solifenacin in treating overactive bladder symptoms in Parkinson disease, with fewer adverse effects, supporting behavioral therapy as a frontline treatment o
Regular physical activity in early Parkinson disease patients is linked to slower brain atrophy in temporoparietal and limbic regions, mediating better preservation of memory and attention over four years.
This study explores medication use and its impact on 8-year mortality among patients with Parkinson disease, identifying potential drug repurposing candidates for treatment.